Kineta Quick Ratio 2014-2024 | KANT
Historical quick ratio values for Kineta (KANT) over the last 10 years.
| Kineta Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2024-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2024-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2023-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2023-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2023-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2023-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2022-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2022-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2022-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2022-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.03B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2019-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2018-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2018-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2017-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2016-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2015-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
